Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: CNS Lesion Clear all
Completed Not applicable Interventional Results available

Assessment of the Embolization of Neurovascular Lesions Using the Penumbra Smart Coil

NCT02729740
View directory record Official record
Conditions
Intracranial Aneurysm
Interventions
Penumbra Smart Coil, Penumbra Coil 400TM (PC400), Penumbra Occlusion DeviceTM(POD)
Device
Lead sponsor
Penumbra Inc.
Industry
Eligibility
Not listed
Enrollment
995 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
71
States / cities
Dothan, Alabama • Mesa, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2021 · Synced Jun 10, 2026, 2:27 PM EDT
Recruiting Phase 2 Interventional

Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity

NCT06299891
View directory record Official record
Conditions
Hypothalamic Obesity, Hypothalamic Tumor, Craniopharyngioma
Interventions
Phentermine / Topiramate Extended Release Oral Capsule [Qsymia], Placebo
Drug · Other
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
6 Years to 28 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Jun 10, 2026, 2:27 PM EDT
Not listed Phase 2 Interventional

A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions

NCT02927340
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
Lorlatinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Effects of YM872 on Stroke Lesion Volume in Acute Stroke Patients

NCT00044070
View directory record Official record
Conditions
Cerebrovascular Accident
Interventions
YM872 (zonampanel)
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
60
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2006 · Synced Jun 10, 2026, 2:27 PM EDT
Completed No phase listed Observational Results available

Barrow Nasal Inventory Survey

NCT01322945
View directory record Official record
Conditions
Pituitary Tumors
Interventions
Not listed
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 80 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 9, 2013 · Synced Jun 10, 2026, 2:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Transcranial Doppler Using Wearable Ultrasound Patch

NCT06073145
View directory record Official record
Conditions
Medical Device Complication, Brain Injuries, Brain Diseases, Stroke, Vasospasm
Interventions
conventional transcranial Doppler probe and wearable ultrasound patch.
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 1Phase 2 Interventional

Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas

NCT01024907
View directory record Official record
Conditions
Adult Brain Tumor, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma, Adult Ependymoma, Adult Grade II Meningioma, Adult Melanocytic Lesion, Adult Meningeal Hemangiopericytoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Pineal Gland Astrocytoma, Adult Pineocytoma, Recurrent Adult Brain Tumor
Interventions
proton beam radiation therapy, quality-of-life assessment, questionnaire administration
Radiation · Procedure · Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 2 Interventional Results available

P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

NCT02633501
View directory record Official record
Conditions
CNS Lesion, Blood Brain Barrier Defect
Interventions
P03277, Gadobenate dimeglumine, MRI
Drug · Device
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
Chicago, Illinois • Boston, Massachusetts • Farmington Hills, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2021 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis

NCT00879658
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
BAF312, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
Cullman, Alabama • San Francisco, California • Centennial, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis

NCT04025554
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Anakinra
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

NCT00676715
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Placebo, Ocrelizumab, Avonex
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
26
States / cities
Phoenix, Arizona • Berkeley, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Jun 10, 2026, 2:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Test of A Model of Representational Knowledge Stored in the Human Prefrontal Cortex

NCT00024908
View directory record Official record
Conditions
Intracranial Central Nervous System Disorder, Mental Disorder, Healthy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
6 Years to 90 Years
Enrollment
949 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.

NCT02792231
View directory record Official record
Conditions
Relapsing Multiple Scelrosis
Interventions
Ofatumumab subcutaneous injection, Teriflunomide-matching placebo capsules, Teriflunomide capsule, Matching placebo of ofatumumab subcutaneous injections
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
955 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
59
States / cities
Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Jun 10, 2026, 2:27 PM EDT
Recruiting Phase 4 Interventional

Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions

NCT03014687
View directory record Official record
Conditions
Antibiotics, Pituitary Adenoma
Interventions
Placebo, Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 84 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Jun 10, 2026, 2:27 PM EDT
Recruiting No phase listed Observational

Abbott Vascular Medical Device Registry

NCT04573660
View directory record Official record
Conditions
Acute Myocardial Infarction, Restenoses, Coronary, Coronary Artery Lesions, Venous Embolism, Arterial Embolism
Interventions
Coronary and peripheral stents, Pacing catheters, Vascular plugs, Measurement and imaging (FFR and OCT), Peripheral dilatation catheters, Coronary dilatation catheters, Coronary and peripheral guidewires, Vessel closure/compression devices, Vascular access introducers
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
3,784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
7
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GTR in Comparison to Copaxone®

NCT01489254
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Glatiramer Acetate (GTR), Glatiramer Acetate (Copaxone®), Placebo
Drug
Lead sponsor
Synthon BV
Industry
Eligibility
18 Years to 55 Years
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
7
States / cities
Irvine, California • Port Charlotte, Florida • Sunrise, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers

NCT04384666
View directory record Official record
Conditions
Parkinson Disease
Interventions
LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection), Neupro 4 mg / 24 Hr. Transdermal Patch
Drug · Other
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Jun 10, 2026, 2:27 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Study to Measure the Effect of Brain Stimulation on Hand Strength and Function in Patients With Brain Tumors

NCT05023434
View directory record Official record
Conditions
Brain Tumor, Brain Cancer, Motor Cortex; Lesion
Interventions
Intraoperative Brain Simulation - Alternate Stimulation Parameters
Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI

NCT01670526
View directory record Official record
Conditions
Traumatic Brain Injury, Cognitive Impairment
Interventions
Rivastigmine Transdermal Patch
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
19 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
8
States / cities
San Diego, California • Miami, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Not applicable Interventional

Feasibility of Using Prism Adaptation to Treat Spatial Neglect and Motor Function in Stroke

NCT02419222
View directory record Official record
Conditions
Stroke
Interventions
Prism Adaptation
Behavioral
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Saddle Brook, New Jersey • West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 20, 2017 · Synced Jun 10, 2026, 2:27 PM EDT
Completed No phase listed Observational

Evaluation of Brain Lesions in HIV-infected Patients for Diagnosis of Primary Central Nervous System Lymphoma

NCT00226304
View directory record Official record
Conditions
HIV Infections, Lymphoma, AIDS-Related
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 10, 2026, 2:27 PM EDT
Recruiting Not applicable Interventional

Multi-functional Neuroprosthetic System for Restoration of Motor Function in Spinal Cord Injury

NCT02329652
View directory record Official record
Conditions
Spinal Cord Injuries, Spinal Cord Injury at C5-C7 Level, Spinal Cord Injury Cervical, Spinal Cord Injury at C5-C7 Level With Complete Lesion, Spinal Cord Injury at C5-C7 Level With Incomplete Lesion
Interventions
Networked Neuroprosthetic System for Grasp and Trunk
Device
Lead sponsor
Anne Bryden
Other
Eligibility
17 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2031
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Jun 10, 2026, 2:27 PM EDT
Terminated Not applicable Interventional Results available

Evaluation of t-RFA and RF-TVA Prior to/Following Radiation Therapy to Treat Painful Metastatic Vertebral Body Tumor(s)

NCT02225223
View directory record Official record
Conditions
Metastatic Lesions in Vertebral Bodies
Interventions
STAR™ Tumor Ablation System, StabiliT® Vertebral Augmentation System
Device
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
14
States / cities
Los Angeles, California • Torrance, California • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

NCT03996447
View directory record Official record
Conditions
CNS Lesion, Blood Brain Barrier Defect
Interventions
gadopiclenol, Gadobutrol 1Mmol/mL Solution for Injection Vial
Drug
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Panorama City, California • Farmington, Connecticut • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Jun 10, 2026, 2:27 PM EDT